Ginkgo Bioworks Holdings, Inc. Material Event: The Biosecurity Spin-off

1. What happened?

Ginkgo Bioworks has officially sold its "Biosecurity" business, Concentric by Ginkgo, to Tower Biosecurity (a company controlled by Perimeter Systems). Ginkgo transferred all assets, intellectual property, and operations to Tower. In exchange, Ginkgo received a 20% ownership stake in Tower Biosecurity. This move effectively removes the unpredictable, pandemic-era public health monitoring revenue from Ginkgo’s financial books.

2. When did it happen?

The deal officially closed on April 3, 2026, following the necessary regulatory approvals.

3. Why did it happen?

Ginkgo’s core mission is to be a "biological foundry" for cell programming. While the Biosecurity unit was a major revenue driver during the COVID-19 pandemic, it became a distraction from the main Cell Engineering business. By spinning off this division, Ginkgo is simplifying its operations and cutting costs. The 20% stake allows Ginkgo to keep a foot in the door for future biosecurity success without the heavy burden of managing government health infrastructure.

4. Why does this matter for your portfolio?

Ginkgo is pivoting to be a "pure-play" synthetic biology company to improve its market valuation. Historically, Biosecurity revenue was inconsistent, which often masked the true performance of the Cell Engineering segment.

Financial data from 2023 to 2025 shows that Biosecurity often accounted for over half of Ginkgo’s total revenue. Removing it reveals a smaller, more focused revenue base. It also exposes the true cost of running Ginkgo’s automated lab infrastructure, which currently operates at a loss.

5. Who is affected?

• Investors: Financial reports will look different moving forward. Biosecurity revenue will now be listed as "discontinued operations." You should now judge Ginkgo solely on the performance of its Cell Engineering services and the growth of its foundry platform.
• Customers: Government and private clients have transitioned to Tower Biosecurity. They should see no interruption in service.
• Employees: A significant portion of staff moved to Tower Biosecurity. This reduces Ginkgo’s total headcount and lowers its day-to-day operating expenses.

6. What should you know before you trade?

• The "Burn Rate" Reality: Reported revenue will drop significantly. Don't be alarmed by this top-line decrease; instead, focus on the year-over-year growth of the Cell Engineering segment to see if the core business is actually scaling. The company’s "burn rate"—the speed at which it spends cash—will now more accurately reflect the true cost of the foundry.
• The 20% Stake: This is a minority investment and provides no immediate cash flow. Its value depends entirely on Tower Biosecurity’s future success or a potential future sale.
• Transition Services: Ginkgo is providing temporary IT and facility support to Tower. While Tower pays for these services, this creates a temporary financial link between the two companies that will eventually fade away.

7. What happens next?

Keep an eye on the first-quarter 2026 report. It will offer the first "clean" look at the company’s profit margins without the Biosecurity business. The market will be looking for proof that R&D spending is successfully turning into long-term, recurring Cell Engineering revenue. This is the single most important metric for Ginkgo’s long-term survival and path to profitability.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.